Sonus Pharmaceuticals (SNUS) Comments on Strategic Initiatives: Reduces Headcount and Qtr. Cash Burn
Tweet Send to a Friend
Sonus Pharmaceuticals, Inc. (Nasdaq: SNUS) today announced that it has focused on the clinical development of SN2310, a Phase 1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
